Fierce Pharma
NOVEMBER 15, 2023
In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. | In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival.
Clarivate
NOVEMBER 15, 2023
Every year, the unveiling of the Highly Cited Researchers list sparks anticipation within the global research community as both researchers and their affiliated institutions or organizations scrutinize the list. Today, we present our 2023 list , recognizing 6,849 individuals from more than 1,300 institutions across 67 countries and regions. These Highly Cited Researchers stand out for their significant and broad influence in various scientific and social science domains, representing a small fra
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 15, 2023
How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? | How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? The craze is such that Germany’s drug regulator is considering banning the export of Ozempic, according to a report in Der Spiegel magazine.
PharmExec
NOVEMBER 15, 2023
Defencath is indicated for the prevention and treatment of catheter-related bloodstream infections in adults with kidney failure administered chronic hemodialysis via a central venous catheter.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
NOVEMBER 15, 2023
If you’re curious about the pitfalls of CAR-T drug commercialization, look no further than Bristol Myers Squibb’s Abecma partner 2seventy bio. | After reporting a sizable revenue decline for its BMS-parntered multiple myeloma cell therapy in 2023’s third quarter, 2seventy stands out as a prime example of the dangers of scaling up a process before suffering lower-than-expected demand, one group of analysts contends.
European Pharmaceutical Review
NOVEMBER 15, 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC) Tecentriq ® (atezolizumab). Roche’s monoclonal antibody cancer immunotherapy was recommended for all indications in which Tecentriq intravenous (IV) has been previously approved, including certain lung, liver, bladder and breast cancer types.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 15, 2023
Gilead Sciences is increasing its stake in partner Arcellx and expanding the cell therapy alliance the companies started in 2022. The deal expands the lead partnered program to more cancers and gives Gilead a chance at another Arcellx cell therapy candidate made with different technology.
PharmExec
NOVEMBER 15, 2023
Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” conditions, capturing the landscape of five expanding therapeutic areas: weight loss, osteoarthritis, Alzheimer’s disease, COPD, and psychedelics.
MedCity News
NOVEMBER 15, 2023
A hearing healthcare veteran consultant, who has significant hearing loss, describes 7 market-tested best practices. Understanding the consumer-patient journey is crucial to developing strategic priorities for companies across hearing healthcare, from hearing aids to cochlear implants to gene/drug therapy.
European Pharmaceutical Review
NOVEMBER 15, 2023
Researchers have demonstrated the feasibility of on-line mass spectrometry (MS) measurement using an on-line micro simulated moving bed chromatography (µSMB)- mass spectrometry system. It provides a versatile process analytical technology (PAT) tool by combining the detection power of mass spectrometry for various product attributes with the advantages of continuous on-line analytics.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
NOVEMBER 15, 2023
Cytovale, a San Francisco-based medical diagnostics company, raised $84 million in Series C funds to advance the commercialization of its diagnostic test for early sepsis detection. Using standard blood draws, the test provides results in under 10 minutes. It is meant to detect sepsis in patients who present to hospital emergency departments.
European Pharmaceutical Review
NOVEMBER 15, 2023
Two new production facilities have opened in Europe, Sandoz announced on 10 November 2023. The €150 million facility in Kundl, Austria will produce the antibiotic penicillin, while the new €25 million facility in Holzkirchen, Germany will be Sandoz’s new Biosimilar Development Center. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.
MedCity News
NOVEMBER 15, 2023
There are several ways to know if a digital mental health solution is working, including whether it has proven clinical outcomes or if it’s improving access to care, executives said during a panel discussion.
Pharmaceutical Technology
NOVEMBER 15, 2023
Chief executive Amanda Pritchard says vaccination and screening could make eliminating cervical cancer a reality in the next two decades.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
NOVEMBER 15, 2023
Flexible, portable medical diagnostic devices are the future, augmenting equity and access to quality healthcare. That means designing for patients as well as caregivers, creating devices that are intuitive, easy to use, and easily adaptable to various environments.
PharmaTimes
NOVEMBER 15, 2023
CHD is a common birth defect that affects the development of the heart and brain - News - PharmaTimes
MedCity News
NOVEMBER 15, 2023
At a conference last week, AdventHealth CEO Terry Shaw discussed how his organization fosters a culture in which its workers feel heard and supported. Some of his advice included making necessary changes based on employee feedback and providing ample opportunities for career advancement.
PharmaVoice
NOVEMBER 15, 2023
Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.
MedCity News
NOVEMBER 15, 2023
Government funding plays a major role in the advancement of drugs, including monoclonal antibodies, which are extremely expensive to produce and can take months to develop.
Pharmaceutical Technology
NOVEMBER 15, 2023
The company has struggled this year on the back of reduced Covid-19 medication sales and is now streamlining costs.
PharmExec
NOVEMBER 15, 2023
The eye drops listed in the warning letter are defined as drugs because they are intended to use for the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure of any function of the body.
pharmaphorum
NOVEMBER 15, 2023
Elucid’s $80m round heads latest digital health financings Phil.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
NOVEMBER 15, 2023
Both programmes will be offered to those most at risk of developing STIs - News - PharmaTimes
PharmExec
NOVEMBER 15, 2023
There is no cure for having to remember countless logins/passwords.
pharmaphorum
NOVEMBER 15, 2023
Bayer pulls Aliqopa from US for follicular lymphoma Phil.
Pharmaceutical Commerce
NOVEMBER 15, 2023
Patients with kidney failure administered chronic hemodialysis who received DefenCath showed a statistically significant lower incidence of catheter-related bloodstream infections.
pharmaphorum
NOVEMBER 15, 2023
Australian retail pharmacy enters clinical trials market Phil.
Pharmaceutical Technology
NOVEMBER 15, 2023
The UK JCVI has recommended the addition of chickenpox vaccine to the country's routine immunisation programme for children.
pharmaphorum
NOVEMBER 15, 2023
Gilde’s new investment fund reaches €740m at close Phil.
Clarify Health
NOVEMBER 15, 2023
In the business of healthcare, time is of the essence. Health plans and care delivery organizations face steep competition for customers and patients, so it’s essential to move swiftly to gain customer loyalty and market share when launching a new health plan or service line. But, as the saying goes, only fools rush in. Healthcare leaders need to look at market trends, population health statistics, and other data to make informed growth decisions.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
360 
Let's personalize your content